Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...

Building on its autologous CD19 CAR-T cell therapy obe-cel, Autolus added a CD22 CAR to create AUTO1/22. The dual mechanism is intended to address a major cause of treatment failure. Thursday ...